-
公开(公告)号：US20170088583A1
公开(公告)日：2017-03-30
申请号：US15287042
申请日：2016-10-06
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Guoqiang Wang , Jiang Long , Bin Wang
Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20160136233A1
公开(公告)日：2016-05-19
申请号：US14948876
申请日：2015-11-23
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Jiang Long , In Jong Kim
CPC classification number: A61K38/13 , A61K38/00 , A61K38/21 , A61K45/06 , C07K7/645 , Y02A50/463 , A61K2300/00
Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
-
113.发明申请公开(公告)号：US20160130297A1
公开(公告)日：2016-05-12
申请号：US14934122
申请日：2015-11-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Ruichao Shen , Xuechao Xing
CPC classification number: C07J41/0061 , C07J41/0088 , C07J43/003
Abstract: The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8和m如本文所定义，包含这些化合物的药物组合物和使用方法 的这些化合物用于治疗TGR5介导的疾病或病症。
-
公开(公告)号：US08921573B2
公开(公告)日：2014-12-30
申请号：US14253976
申请日：2014-04-16
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Datong Tang , Guoyou Xu , Xiaowen Peng , Lu Ying , Ce Wang , Hui Cao , Jiang Long , In Jong Kim , Guoqiang Wang , Yao-Ling Qiu , Yat Sun Or
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：
-
公开(公告)号：US20140316143A1
公开(公告)日：2014-10-23
申请号：US14253976
申请日：2014-04-16
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Datong Tang , Guoyou Xu , Xiaowen Peng , Lu Ying , Ce Wang , Hui Cao , Jiang Long , In Jong Kim , Guoqiang Wang , Yao-Ling Qiu , Yat Sun Or
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：
-
Patent Agency Ranking
公开(公告)号：US20140219958A1
公开(公告)日：2014-08-07
申请号：US14169387
申请日：2014-01-31
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Jay R. Luly , Jun Ma , Guoqiang Wang , Yat Sun Or
IPC: A61K31/7072 , A61K45/06 , C07H17/02
CPC classification number: A61K31/7072 , A61K31/13 , A61K31/7056 , A61K38/21 , A61K45/06 , C07H19/06 , C07H19/10 , C07H19/11 , A61K2300/00
Abstract: In one aspect, the invention provides compounds represented by Formula I, and pharmaceutically acceptable salts, esters, stereoisomers, tautomers, solvates, and combinations thereof, pharmaceutical compositions comprising these compounds and the use of these compounds for treating a viral infection in a subject.
Abstract translation: 一方面，本发明提供由式I表示的化合物及其药学上可接受的盐，酯，立体异构体，互变异构体，溶剂合物及其组合，包含这些化合物的药物组合物以及这些化合物用于治疗受试者的病毒感染的用途。
-
公开(公告)号：US20140135485A1
公开(公告)日：2014-05-15
申请号：US14047424
申请日：2013-10-07
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Guoqiang Wang , Ly Tam Phan , Dequiang Niu , Nha Huu Vo , Yao-Ling Qiu , Yanchun Wang , Marina V. Busuek , Ying Hou , Yulin Peng , Heejin Kim , Tongzhu Liu , Jay Judson Farmer , Guoyou Xu
IPC: C07H17/08
CPC classification number: C07H17/08 , A61K31/7052 , A61K45/06 , Y02A50/401 , Y02A50/478 , A61K2300/00
Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。
-
公开(公告)号：US12018017B2
公开(公告)日：2024-06-25
申请号：US18073728
申请日：2022-12-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
公开(公告)号：US12006291B2
公开(公告)日：2024-06-11
申请号：US18095155
申请日：2023-01-10
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Kaicheng Zhu , Tao Wang , Jiajun Zhang , Hui Cao , Ruichao Shen , Guoqiang Wang , George G. Wu , Yat Sun Or
IPC: C07D209/42
CPC classification number: C07D209/42
Abstract: The present invention relates to processes for preparing a Compound (1):
or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.-
120.发明公开公开(公告)号：US20240132476A1
公开(公告)日：2024-04-25
申请号：US18383949
申请日：2023-10-25
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
-
-
-
-
-
-
-
-
Search Results
154
records
(took 0.035 seconds)
